21 December 2016 ORYZON Receives a New 0.8 M USD Public Grant to Explore New Indications for Epigenetic Inhibitors
6 December 2016 ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting
7 November 2016 ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)
24 October 2016 ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
14 September 2016 ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award